SMMTのチャート
SMMTの企業情報
symbol | SMMT |
---|---|
会社名 | Summit Therapeutics PLC (サミット・セラピュ―ティクス) |
分野(sector) | Health Care ヘルスケア |
産業(industry) | Major Pharmaceuticals |
業種 | ― 医療関連(Health Care) |
概要 | 事業概要 -- サミット・セラピュ―ティクスはイギリスのバイオ医薬品メ―カ―。既存疾病または治療法のない疾病の新規治療薬の開発、商品化に焦点を当てる。主に、致命的な筋肉消耗疾患のデュシェンヌ型筋ジストロフィ―とクロストリジウム・ディフィシル細菌感染症の治療法の発見、および新規医薬品の開発に注力する。本社所在地はアビングドン。 Summit Therapeutics, empowered by its Discuva Platform, the Company's innovative antibiotic discovery engine, led by Dr. Ventzislav Stefanov and supported by BARDA and Carb-X funding, intends to be the leader in patient and physician friendly paradigm shifting antibiotic innovation. Its new mechanism antibiotics are designed to become the patient-friendly, new era standard-of-care, by working in harmony with the human microbiome to treat prospective patients suffering from infectious disease, initially focussing on Clostridioides difficile infections ("CDI") which is estimated to impact over 3 million patients worldwide annually. Commercialization of ridinilazole for the treatment of CDI is subject to regulatory approvals. The overriding objective of Summit Therapeutics is to create value for patients, hospital infectious disease care givers, community based infectious disease healthcare providers, as well as healthcare payors around the world. Currently, Summit's lead product candidate ridinilazole is engaged in two global phase III trials, Ri-CoDIFy 1 & 2, each enrolling 680 patients vs standard of care (Vancomycin) for the treatment of C. difficile infections. |
本社所在地 | 136a Eastern Avenue Milton Park Abingdon Oxfordshire OX14 4SB GBR |
代表者氏名 | ― |
代表者役職名 | ― |
電話番号 | ― |
設立年月日 | - |
市場名 | NASDAQ National Market System |
ipoyear | 2015年 |
従業員数 | 76人 |
url | www.summitplc.com |
nasdaq_url | https://www.nasdaq.com/symbol/smmt |
adr_tso | 6262462 |
EBITDA | EBITDA ー |
終値(lastsale) | 2.03 |
時価総額(marketcap) | 12712797.86 |
時価総額 | 時価総額 ― |
売上高 | 売上高 -- |
企業価値(EV) | 企業価値(EV) ー |
当期純利益 | 当期純利益 -- |
決算概要 | 決算概要 -- |
SMMTのテクニカル分析
SMMTのニュース
Boom Or Bust: Where Does Summit Therapeutics Inc. (NASDAQ: SMMT) Stock Go From Here? 2022/06/24 11:00:00 Marketing Sentinel
During the last session, Summit Therapeutics Inc. (NASDAQ:SMMT)’s traded shares were 1.08 million, with the beta value of the company hitting 1.11. At the end of the trading day, the stock’s price was $1.13, reflecting an intraday gain of 4.63% or $0.05. The 52-week high for the SMMT share is $8.39, that puts it down … Boom Or Bust: Where Does Summit Therapeutics Inc. (NASDAQ: SMMT) Stock Go From Here? Read More »
Summit Therapeutics stock drops postmarket on $100M rights offering 2022/06/22 21:00:27 Seeking Alpha
Summit Therapeutics (SMMT) stock dropped ~17% postmarket after the firm announced a rights offering for shareholders of record as of market close on Jul
Ankur Dhingra is the new CFO of Summit Therapeutics 2022/06/01 12:48:42 Seeking Alpha
Summit Therapeutics (SMMT) appoints Ankur Dhingra as CFO, effective immediately.Mr
77 Biggest Movers From Yesterday 2022/06/01 09:02:22 Benzinga
Gainers TherapeuticsMD, Inc. (NASDAQ: TXMD ) shares climbed 364% to close at $9.93 on Tuesday after the company announced it has entered into a definitive merger agreement to be acquired by an affiliate of EW Healthcare Partners. JanOne Inc. (NASDAQ: JAN ) gained 66.5% to close at $3.73 after the company announced it sold GeoTraq to SPYR Technologies in a $13.5 million transaction. Mullen Automotive, Inc. (NASDAQ: MULN ) jumped 44.9% to settle at $1.40 after the company announced results of its solid-state polymer battery testing with the Battery Innovation Center in Indiana. Studio City International Holdings Limited (NASDAQ: MSC ) gained 43.3% to close at $3.21. CatchMark Timber Trust, Inc. (NYSE: CTT ) shares climbed 42.1% to close at $11.79 after the company and PotlatchDeltic announced they have entered into a definitive agreement to combine in an all-stock transaction. Xcel Brands, Inc. (NASDAQ: XELB ) gained 36.7% to settle at $1.49 after the company announced WHP will purchase a controlling 70% interest in fashion brand Isaac Mizrahi.
Summit Therapeutics GAAP EPS of -$0.22, revenue of $0.25M 2022/05/11 20:50:23 Seeking Alpha
Summit Therapeutics press release (SMMT): Q1 GAAP EPS of -$0.22.Revenue of $0.25M (+31.6% Y/Y).
Boom Or Bust: Where Does Summit Therapeutics Inc. (NASDAQ: SMMT) Stock Go From Here? 2022/06/24 11:00:00 Marketing Sentinel
During the last session, Summit Therapeutics Inc. (NASDAQ:SMMT)’s traded shares were 1.08 million, with the beta value of the company hitting 1.11. At the end of the trading day, the stock’s price was $1.13, reflecting an intraday gain of 4.63% or $0.05. The 52-week high for the SMMT share is $8.39, that puts it down … Boom Or Bust: Where Does Summit Therapeutics Inc. (NASDAQ: SMMT) Stock Go From Here? Read More »
Summit Therapeutics stock drops postmarket on $100M rights offering 2022/06/22 21:00:27 Seeking Alpha
Summit Therapeutics (SMMT) stock dropped ~17% postmarket after the firm announced a rights offering for shareholders of record as of market close on Jul
Ankur Dhingra is the new CFO of Summit Therapeutics 2022/06/01 12:48:42 Seeking Alpha
Summit Therapeutics (SMMT) appoints Ankur Dhingra as CFO, effective immediately.Mr
77 Biggest Movers From Yesterday 2022/06/01 09:02:22 Benzinga
Gainers TherapeuticsMD, Inc. (NASDAQ: TXMD ) shares climbed 364% to close at $9.93 on Tuesday after the company announced it has entered into a definitive merger agreement to be acquired by an affiliate of EW Healthcare Partners. JanOne Inc. (NASDAQ: JAN ) gained 66.5% to close at $3.73 after the company announced it sold GeoTraq to SPYR Technologies in a $13.5 million transaction. Mullen Automotive, Inc. (NASDAQ: MULN ) jumped 44.9% to settle at $1.40 after the company announced results of its solid-state polymer battery testing with the Battery Innovation Center in Indiana. Studio City International Holdings Limited (NASDAQ: MSC ) gained 43.3% to close at $3.21. CatchMark Timber Trust, Inc. (NYSE: CTT ) shares climbed 42.1% to close at $11.79 after the company and PotlatchDeltic announced they have entered into a definitive agreement to combine in an all-stock transaction. Xcel Brands, Inc. (NASDAQ: XELB ) gained 36.7% to settle at $1.49 after the company announced WHP will purchase a controlling 70% interest in fashion brand Isaac Mizrahi.
Summit Therapeutics GAAP EPS of -$0.22, revenue of $0.25M 2022/05/11 20:50:23 Seeking Alpha
Summit Therapeutics press release (SMMT): Q1 GAAP EPS of -$0.22.Revenue of $0.25M (+31.6% Y/Y).
Analysts Expect Summit Therapeutics Inc. (NASDAQ:SMMT) Will Post Earnings of -$0.29 Per Share 2021/11/05 12:28:42 Dakota Financial News
Analysts expect that Summit Therapeutics Inc. (NASDAQ:SMMT) will post ($0.29) earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have made estimates for Summit Therapeutics earnings. Summit Therapeutics posted earnings of ($0.25) per share during the same quarter last year, which would indicate a negative year over year growth []
Citigroup Inc. Has $53,000 Holdings in Summit Therapeutics Inc. (NASDAQ:SMMT) 2021/10/23 08:18:42 Dakota Financial News
Citigroup Inc. cut its stake in shares of Summit Therapeutics Inc. (NASDAQ:SMMT) by 53.3% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 7,165 shares of the companys stock after selling 8,167 shares during the period. Citigroup Inc.s holdings in Summit Therapeutics were []
Summit Therapeutics Appoints Prominent Biotech Attorney and Advisor Kenneth A. Clark to Its Board of Directors 2021/10/08 12:30:00 Intrado Digital Media
Cambridge, MA, Oct. 08, 2021 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) today announced that Kenneth A. Clark, JD, has been appointed to our Board of Directors, effective immediately. Mr. Clark is currently a partner at Wilson Sonsini Goodrich & Rosati (WSGR) based out of the firms Palo Alto, CA, office.
Futures Bounce On Evergrande Reprieve With Fed Looming 2021/09/22 12:05:16 Zero Hedge
Futures Bounce On Evergrande Reprieve With Fed Looming Despite today''s looming hawkish FOMC meeting in which Powell is widely expected to unveil that tapering is set to begin as soon as November and where the Fed''s dot plot may signal one rate hike in 2022, futures climbed as investor concerns over China''s Evergrande eased after the property developer negotiated a domestic bond payment deal. Commodities rallied while the dollar was steady. Contracts on the S&P 500 and Nasdaq 100 flipped from losses to gains as Chinas central bank boosted liquidity when it injected a gross 120BN in yuan, the most since January ... and investors mulled a vaguely-worded statement from the troubled developer about an interest payment. S&P 500 E-minis were up 23.0 points, or 0.53%, at 7:30 a.m. ET. Dow E-minis were up 199 points, or 0.60%, and Nasdaq 100 E-minis were up 44.00 points, or 0.29%. Among individual stocks, Fedex fell 5.8% after the delivery company cut its profit outlook on higher costs and stalled growth in shipments.